Brendan Teehan

CIK: 0001891900

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (12.5%)

Position reduction

Option Exercises (M)2 (25.0%)

Derivative conversions

Awards (A)4 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (12.5%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

PCRX

Pacira BioSciences, Inc.

Officer

ACAD

ACADIA PHARMACEUTICALS INC

Officer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

PCRX
Pacira BioSciences, Inc.
Feb 11, 2026
Award(A)
Direct
51.7K shares-
PCRX
Pacira BioSciences, Inc.
Jan 30, 2026
Tax Payment(F)
Direct
5.2K shares at avg. $20.54$106K
PCRX
Pacira BioSciences, Inc.
Dec 31, 2025
Award(A)
Direct
402 shares at avg. $10.76$4K
PCRX
Pacira BioSciences, Inc.
Feb 4, 2025
Award(A)
Stock Option (Right to Buy)
Direct
99.5K shares at avg. $26.59-
PCRX
Pacira BioSciences, Inc.
Feb 1, 2025
Award(A)
Direct
54K shares-
ACAD
ACADIA PHARMACEUTICALS INC
Nov 19, 2024
Sale(S)
Direct
10.3K shares at avg. $16.81$174K
ACAD
ACADIA PHARMACEUTICALS INC
Nov 17, 2024
Exercise(M)
Direct
9.9K shares-
ACAD
ACADIA PHARMACEUTICALS INC
Nov 17, 2024
Exercise(M)
Direct
9.9K shares-

		Type	Shares	Price		Ownership
Feb 11, 2026	PCRX Pacira BioSciences, Inc.	Award(A)	51,714	-	$0	Direct
Jan 30, 2026	PCRX Pacira BioSciences, Inc.	Tax Payment(F)	5,182	$20.54	$106,438	Direct
Dec 31, 2025	PCRX Pacira BioSciences, Inc.	Award(A)	402	$10.76	$4,330	Direct
Feb 4, 2025	PCRX Pacira BioSciences, Inc.	Award(A) Stock Option (Right to Buy)	99,500	$26.59	-	Direct
Feb 1, 2025	PCRX Pacira BioSciences, Inc.	Award(A)	54,000	-	-	Direct
Nov 19, 2024	ACAD ACADIA PHARMACEUTICALS INC	Sale(S)	10,329	$16.81	$173,630	Direct
Nov 17, 2024	ACAD ACADIA PHARMACEUTICALS INC	Exercise(M)	9,913	-	$0	Direct
Nov 17, 2024	ACAD ACADIA PHARMACEUTICALS INC	Exercise(M)	9,913	-	$0	Direct

1-8 of 8 transactions

About Teehan Brendan

Teehan Brendan (SEC CIK 0001891900) files insider reports with the SEC as Chief Commercial Officer of Pacira BioSciences, Inc. (PCRX) and EVP, COO, HEAD OF COMMERCIAL of ACADIA PHARMACEUTICALS INC (ACAD).

Signal8 holds 6 ownership filings by Teehan Brendan (1 Form 3, 5 Form 4), filed between Nov 19, 2024 and Feb 13, 2026. Those filings report 8 transactions, from Nov 17, 2024 to Feb 11, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Teehan Brendan's filings is in BRISBANE, CA.

Recent filings by Teehan Brendan

Feb 11, 2026: Grant or award of PCRX shares (Form 4, code A).
Jan 30, 2026: Tax withholding of PCRX shares (Form 4, code F).
Dec 31, 2025: Grant or award of PCRX shares (Form 4, code A).
Feb 4, 2025: Grant or award of PCRX derivative securities (Form 4, code A).
Feb 1, 2025: Grant or award of PCRX shares (Form 4, code A).

Other insiders filing for Pacira BioSciences, Inc. (PCRX)

RIKER LAUREN, Senior Vice President, Finance
SLONIN JONATHAN, Chief Medical Officer
Hirawat Samit, Director
CHRISTIE CHRISTOPHER, Director
WIGGANS THOMAS G, Director
Young Alethia, Director

How to read Form 4 transaction codes